A prospective PET study of patients with glioblastoma multiforme

Andersen, P; Blinkenberg, Morten; Lassen, Ulrik; Kosteljanetz, Michael; Wagner, Aase; Poulsen, Hans Skovgaard; Sørensen, P. Soelberg; Paulson, Olaf B.

doi:10.1111/j.1600-0404.2006.00628.x

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MRI acquisition was performed according to the published paper 13 . In detail, an 8‐channel head‐matrix coil obtained MRI images on a 3.0 T MR System (Discovery MR750, GE Healthcare, Milwaukee, WI, USA).…”

Section: Methodsmentioning

confidence: 99%

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

Liu

Cheng

et al. 2021

Journal of Neuroimaging

View full text Add to dashboard Cite

Background and purpose: To compare and characterize metabolic features of high-and low-grade glioma tumors using 68 Ga-PSMA-617 and 18 F-FDG positron emission tomography/computed tomography (PET/CT).Methods: Thirty patients who underwent both 68 Ga-PSMA-617 and 18 F-FDG PET/CT over 2 consecutive days and then underwent surgical treatment were retrospectively identified. All tumors were diagnosed histologically. This report includes 16 high-grade glioma (HGG) and 14 low-grade glioma (LGG) tumors. Standard uptake value (SUV) and target to nontarget (T/NT) were quantitatively investigated through the entire tumor region. Statistical analyses were performed using area under the curve (AUC) and comparison of two means.

show abstract

Section: Methodsmentioning

confidence: 99%

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

Liu

Cheng

et al. 2021

Journal of Neuroimaging

View full text Add to dashboard Cite

show abstract

“…A decrease in tumor FDG uptake using scintillation counting on excised tumors following radiotherapy was reported in mouse mammary carcinomas and a rat hepatoma (48). More recently, several reports have shown that chemotherapy (10, 49, 51) and radiotherapy (13, 51, 52) results in early increases in FDG uptake of brain tumors in humans. This contradiction has yet to be adequately explained.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Imaging Biomarkers

Galbán

Bhojani

Lee

et al. 2010

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Functional imaging biomarkers of cancer treatment response offer the potential for early determination of outcome through the assessment of biochemical, physiologic, and microenvironmental readouts. Cell death may result in an immunologic response, thus complicating the interpretation of biomarker readouts. This study evaluated the temporal effect of treatment-associated inflammatory activity on diffusion magnetic resonance imaging and 2-[ Experimental Design: Rats with intracerebral 9L gliosarcomas were separated into four groups consisting of control, an immunosuppressive agent dexamethasone (Dex), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and BCNU+Dex. Animals were imaged using diffusion-weighted magnetic resonance imaging and FDG-PET at 0, 3, and 7 days posttreatment.Results: In the BCNU-and BCNU+Dex-treated animal groups, diffusion values increased progressively over the 7-day study period to ∼23% over baseline. The FDG percentage change of standard uptake value decreased at day 3 (−30.9%) but increased over baseline levels at day 7 (+20.1%). FDG-PET of BCNU+Dex-treated animals were found to have percentage of standard uptake value reductions of −31.4% and −24.7% at days 3 and 7, respectively, following treatment. Activated macrophages were observed on day 7 in the BCNU treatment group with much fewer found in the BCNU+Dex group.Conclusions: Results revealed that treatment-associated inflammatory response following tumor therapy resulted in the accentuation of tumor diffusion response along with a corresponding increase in tumor FDG uptake due to the presence of glucose-consuming activated macrophages. The dynamics and magnitude of potential inflammatory response should be considered when interpreting imaging biomarker results. Clin Cancer Res; 16(5); 1542-52. ©2010 AACR.

show abstract

A prospective PET study of patients with glioblastoma multiforme

Abstract: Our study did not show a gain of PET compared with structural imaging in the prospective evaluation of GBM. We found a difference in metabolic increase and tumor growth between the two treatment regimens, although this finding has limited relevance due to the design of the study.

Cited by 2 publications

References 29 publications

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Imaging Biomarkers

Contact Info

Product

Resources

About

A prospective PET study of patients with glioblastoma multiforme

Abstract: Our study did not show a gain of PET compared with structural imaging in the prospective evaluation of GBM. We found a difference in metabolic increase and tumor growth between the two treatment regimens, although this finding has limited relevance due to the design of the study.

Cited by 2 publications

References 29 publications

PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Imaging Biomarkers

Contact Info

Product

Resources

About

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas

PET/CT using ⁶⁸Ga‐PSMA‐617 versus ¹⁸F‐fluorodeoxyglucose to differentiate low‐ and high‐grade gliomas